Literature DB >> 29377584

Generation of full-thickness skin equivalents using hair follicle-derived primary human keratinocytes and fibroblasts.

Anna Löwa1, Annika Vogt2, Sabine Kaessmeyer3, Sarah Hedtrich1.   

Abstract

Skin equivalents are increasingly used as human-based test systems for basic and preclinical research. Most of the established skin equivalents are composed of primary keratinocytes and fibroblasts, isolated either from excised human skin or juvenile foreskin following circumcisions. Although the potential of hair follicle-derived cells for the generation of skin equivalents has been shown, this approach normally requires microdissections from the scalp for which there is limited subject compliance or ethical approval. In the present study, we report a novel method to isolate and cultivate keratinocytes and fibroblasts from plucked hair follicles that were then used to generate skin equivalents. The procedure is non-invasive, inflicts little-pain, and may allow easy access to patient-derived cells without taking punch biopsies. Overall, minor differences in morphology, ultrastructure, expression of important structural proteins, or barrier function were observed between skin equivalents generated from hair follicle-derived or interfollicular keratinocytes and fibroblasts. Interestingly, improved basal lamina formation was seen in the hair follicle-derived skin equivalents. The presented method here allows easy and non-invasive access to keratinocytes and fibroblasts from plucked hair follicles that may be useful particularly for the generation of skin disease equivalents.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  hair follicle; interfollicular keratinocytes and fibroblasts; outer rooth sheath; skin equivalents

Mesh:

Year:  2018        PMID: 29377584     DOI: 10.1002/term.2646

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  7 in total

Review 1.  Nanocarriers for Skin Applications: Where Do We Stand?

Authors:  Neha Tiwari; Ernesto Rafael Osorio-Blanco; Ana Sonzogni; David Esporrín-Ubieto; Huiyi Wang; Marcelo Calderón
Journal:  Angew Chem Int Ed Engl       Date:  2021-10-01       Impact factor: 16.823

2.  How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.

Authors:  Monika Schäfer-Korting; Christian Zoschke
Journal:  Handb Exp Pharmacol       Date:  2021

3.  A Simple Method for the Production of Human Skin Equivalent in 3D, Multi-Cell Culture.

Authors:  Łukasz Szymański; Krystyna Jęderka; Aleksandra Cios; Martyna Ciepelak; Aneta Lewicka; Wanda Stankiewicz; Sławomir Lewicki
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

4.  Ultrastructural and Molecular Analysis of Ribose-Induced Glycated Reconstructed Human Skin.

Authors:  Roberta Balansin Rigon; Sabine Kaessmeyer; Christopher Wolff; Christian Hausmann; Nan Zhang; Michaela Sochorová; Andrej Kováčik; Rainer Haag; Kateřina Vávrová; Martina Ulrich; Monika Schäfer-Korting; Christian Zoschke
Journal:  Int J Mol Sci       Date:  2018-11-08       Impact factor: 5.923

5.  A Tissue-Engineered Human Psoriatic Skin Model to Investigate the Implication of cAMP in Psoriasis: Differential Impacts of Cholera Toxin and Isoproterenol on cAMP Levels of the Epidermis.

Authors:  Mélissa Simard; Sophie Morin; Geneviève Rioux; Rachelle Séguin; Estelle Loing; Roxane Pouliot
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

6.  Beyond Ca2+ signalling: the role of TRPV3 in the transport of NH4.

Authors:  Hendrik Liebe; Franziska Liebe; Gerhard Sponder; Sarah Hedtrich; Friederike Stumpff
Journal:  Pflugers Arch       Date:  2021-10-19       Impact factor: 4.458

7.  FLIM for Evaluation of Difference in Metabolic Status between Native and Differentiated from iPSCs Dermal Papilla Cells.

Authors:  Alena Kashirina; Alena Gavrina; Artem Mozherov; Dmitriy Kozlov; Daria Kuznetsova; Ekaterina Vorotelyak; Elena Zagaynova; Ekaterina Kalabusheva; Aleksandra Kashina
Journal:  Cells       Date:  2022-09-01       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.